11 results on '"Vilc V."'
Search Results
2. Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases
- Author
-
Valiulis, A., Bousquet, J., Veryga, A., Suprun, U., Sergeenko, D., Cebotari, S., Borelli, D., Pietikainen, S., Banys, J., Agache, I., Billo, N. E., Bush, A., Chkhaidze, I., Dubey, L., Fokkens, W. J., Grigg, J., Haahtela, T., Julge, K., Katilov, O., Khaltaev, N., Odemyr, M., Palkonen, S., Savli, R., Utkus, A., Vilc, V., Alasevicius, T., Bedbrook, A., Bewick, M., Chorostowska-Wynimko, J., Danila, E., Hadjipanayis, A., Karseladze, R., Kvedariene, V., Lesinskas, E., Münter, L., Samolinski, B., Sargsyan, S., Sitkauskiene, B., Somekh, D., Vaideliene, L., Valiulis, A., and Hellings, P. W. more...
- Published
- 2019
- Full Text
- View/download PDF
Catalog
3. Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study
- Author
-
Noguera-Julian A., Calzada-Hernandez J., Brinkmann F., Roy R. B., Bilogortseva O., Buettcher M., Carvalho I., Chechenyeva V., Falcon L., Goetzinger F., Guerrero-Laleona C., Hoffmann P., Jelusic M., Niehues T., Ozere I., Shackley F., Suciliene E., Welch S. B., Scholvinck E. H., Ritz N., Tebruegge M., Curtis N., Villanueva P., Marais B., Britton P., Clark J., Pichler J., Zschocke A., Bogyi M., Dreesman A., Mouchet F., Velizarova S., Pavic I., Nygaard U., Pulsen A., Kontturi A., Salo E., Chadelat K., Kruger R., Tee S., Ahrens F., Barker M., Zimmermann T., Schulze-Sturm U., Kaiser-Labusch P., Tsolia M., Ghanaie O. M., Buonsenso D., Lo Vecchio A., Ivaskeviciene I., Vilc V., Smyrnaios A., Arbore A. S., Starshinova A., Solovic I., Krivec U., Aldeco M., Espiau M., Soriano-Arandes A., Neth O., Santiago B., Gomez-Pastrana D., Blazquez D., Bustillo M., Perez-Porcuna T. M., Cilleruelo M. J., Kotz K., Bennet R., Relly C., Niederer-Loher A., Rochat I., Pavskyi S., Riordan A., Doherty C., Bamford A., Shingadia D., Emonts M., Ferreras-Antolin L., McMaster P., Moriarty P., Noguera-Julian, A., Calzada-Hernandez, J., Brinkmann, F., Roy, R. B., Bilogortseva, O., Buettcher, M., Carvalho, I., Chechenyeva, V., Falcon, L., Goetzinger, F., Guerrero-Laleona, C., Hoffmann, P., Jelusic, M., Niehues, T., Ozere, I., Shackley, F., Suciliene, E., Welch, S. B., Scholvinck, E. H., Ritz, N., Tebruegge, M., Curtis, N., Villanueva, P., Marais, B., Britton, P., Clark, J., Pichler, J., Zschocke, A., Bogyi, M., Dreesman, A., Mouchet, F., Velizarova, S., Pavic, I., Nygaard, U., Pulsen, A., Kontturi, A., Salo, E., Chadelat, K., Kruger, R., Tee, S., Ahrens, F., Barker, M., Zimmermann, T., Schulze-Sturm, U., Kaiser-Labusch, P., Tsolia, M., Ghanaie, O. M., Buonsenso, D., Lo Vecchio, A., Ivaskeviciene, I., Vilc, V., Smyrnaios, A., Arbore, A. S., Starshinova, A., Solovic, I., Krivec, U., Aldeco, M., Espiau, M., Soriano-Arandes, A., Neth, O., Santiago, B., Gomez-Pastrana, D., Blazquez, D., Bustillo, M., Perez-Porcuna, T. M., Cilleruelo, M. J., Kotz, K., Bennet, R., Relly, C., Niederer-Loher, A., Rochat, I., Pavskyi, S., Riordan, A., Doherty, C., Bamford, A., Shingadia, D., Emonts, M., Ferreras-Antolin, L., Mcmaster, P., and Moriarty, P. more...
- Subjects
reactivation ,Disease ,anti-TNF-alpha ,0302 clinical medicine ,Medicine ,children ,030212 general & internal medicine ,JUVENILE IDIOPATHIC ARTHRITIS ,Child ,Anti–TNF-alpha ,RISK ,Latent tuberculosis ,GAMMA RELEASE ASSAYS ,Miliary tuberculosi ,SERIOUS INFECTION ,Infectious Diseases ,tuberculosis ,anti–TNF-alpha ,medicine.drug ,miliary tuberculosis ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,Miliary tuberculosis ,Tuberculosis ,Adolescent ,CORTICOSTEROIDS ,Tuberculin ,DIAGNOSIS ,CLASSIFICATION ,03 medical and health sciences ,Necrosis ,Latent Tuberculosis ,Internal medicine ,SURVEILLANCE ,INFLIXIMAB ,Humans ,Retrospective Studies ,030203 arthritis & rheumatology ,business.industry ,Tuberculin Test ,Tumor Necrosis Factor-alpha ,Retrospective cohort study ,medicine.disease ,FACTOR INHIBITORS ,Infliximab ,Clinical research ,business ,Interferon-gamma Release Tests - Abstract
Background In adults, anti–tumor necrosis factor-α (TNF-α) therapy is associated with progression of latent tuberculosis (TB) infection (LTBI) to TB disease, but pediatric data are limited. Methods Retrospective multicenter study within the Paediatric Tuberculosis Network European Trials Group, capturing patients Results Sixty-six tertiary healthcare institutions providing care for children with TB participated. Nineteen cases were identified: Crohn’s disease (n = 8; 42%) and juvenile idiopathic arthritis (n = 6; 32%) were the commonest underlying conditions. Immune-based TB screening (tuberculin skin test and/or interferon-γ release assay) was performed in 15 patients before commencing anti–TNF-α therapy but only identified 1 LTBI case; 13 patients were already receiving immunosuppressants at the time of screening. The median interval between starting anti–TNF-α therapy and TB diagnosis was 13.1 (IQR, 7.1–20.3) months. All cases presented with severe disease, predominantly miliary TB (n = 14; 78%). One case was diagnosed postmortem. TB was microbiologically confirmed in 15 cases (79%). The median duration of anti-TB treatment was 50 (IQR, 46–66) weeks. Five of 15 (33%) cases who had completed TB treatment had long-term sequelae. Conclusions LTBI screening is frequently false-negative in this patient population, likely due to immunosuppressants impairing test performance. Therefore, patients with immune-mediated diseases should be screened for LTBI at the point of diagnosis, before commencing immunosuppressive medication. Children on anti–TNF-α therapy are prone to severe TB disease and significant long-term morbidity. Those observations underscore the need for robust LTBI screening programs in this high-risk patient population, even in low-TB-prevalence settings. more...
- Published
- 2019
4. Building a tuberculosis-free world: The Lancet Commission on tuberculosis
- Author
-
Reid, M.J.A. (Michael J A), Arinaminpathy, N. (Nimalan), Bloom, A. (Amy), Bloom, B.R. (Barry R), Boehme, C. (Catharina), Chaisson, R. (Richard), Chin, D.P. (Daniel P), Churchyard, G. (Gavin), Cox, H. (Helen), Ditiu, L. (Lucica), Dybul, M. (Mark), Farrar, J. (Jeremy), Fauci, A.S. (Anthony S), Fekadu, E. (Endalkachew), Fujiwara, P.I. (Paula I), Hallett, T.B. (Timothy), Hanson, C.L. (Christy L), Harrington, M. (Mark), Herbert, N. (Nick), Hopewell, P.C. (Philip C), Ikeda, C. (Chieko), Jamison, D.T. (Dean T), Khan, A.J. (Aamir J), Koek, I. (Irene), Krishnan, N. (Nalini), Motsoaledi, A. (Aaron), Pai, M. (Madhukar), Raviglione, M.C. (Mario C), Sharman, A. (Almaz), Small, P.M. (Peter M), Swaminathan, S. (Soumya), Temesgen, Z. (Zelalem), Vassall, A. (Anna), Venkatesan, N. (Nandita), van Weezenbeek, K. (Kitty), Yamey, G. (Gavin), Agins, B.D. (Bruce D), Alexandru, S. (Sofia), Andrews, J.R. (Jason R), Beyeler, N. (Naomi), Bivol, S. (Stela), Brigden, G. (Grania), Cattamanchi, A. (Adithya), Cazabon, D. (Danielle), Crudu, V. (Valeriu), Daftary, A. (Amrita), Dewan, P. (Puneet), Doepel, L.K. (Laurie K), Eisinger, R.W. (Robert W), Fan, V. (Victoria), Fewer, S. (Sara), Furin, J. (Jennifer), Goldhaber-Fiebert, J.D. (Jeremy D), Gomez, G.B. (Gabriela B), Graham, S.M. (Stephen M), Gupta, D. (Devesh), Kamene, M. (Maureen), Khaparde, S. (Sunil), Mailu, E.W. (Eunice W), Masini, E.O. (Enos O), McHugh, L. (Lorrie), Mitchell, E.M.H. (Ellen), Moon, S. (Suerie), Osberg, M. (Michael), Pande, T. (Tripti), Prince, L. (Lea), Rade, K. (Kirankumar), Rao, R. (Raghuram), Remme, M. (Michelle), Seddon, J.A. (James A), Selwyn, C. (Casey), Shete, P. (Priya), Sachdeva, K.S. (Kuldeep S), Stallworthy, G. (Guy), Vesga, J.F. (Juan F), Vilc, V. (Valentina), Goosby, E.P. (Eric P), Reid, M.J.A. (Michael J A), Arinaminpathy, N. (Nimalan), Bloom, A. (Amy), Bloom, B.R. (Barry R), Boehme, C. (Catharina), Chaisson, R. (Richard), Chin, D.P. (Daniel P), Churchyard, G. (Gavin), Cox, H. (Helen), Ditiu, L. (Lucica), Dybul, M. (Mark), Farrar, J. (Jeremy), Fauci, A.S. (Anthony S), Fekadu, E. (Endalkachew), Fujiwara, P.I. (Paula I), Hallett, T.B. (Timothy), Hanson, C.L. (Christy L), Harrington, M. (Mark), Herbert, N. (Nick), Hopewell, P.C. (Philip C), Ikeda, C. (Chieko), Jamison, D.T. (Dean T), Khan, A.J. (Aamir J), Koek, I. (Irene), Krishnan, N. (Nalini), Motsoaledi, A. (Aaron), Pai, M. (Madhukar), Raviglione, M.C. (Mario C), Sharman, A. (Almaz), Small, P.M. (Peter M), Swaminathan, S. (Soumya), Temesgen, Z. (Zelalem), Vassall, A. (Anna), Venkatesan, N. (Nandita), van Weezenbeek, K. (Kitty), Yamey, G. (Gavin), Agins, B.D. (Bruce D), Alexandru, S. (Sofia), Andrews, J.R. (Jason R), Beyeler, N. (Naomi), Bivol, S. (Stela), Brigden, G. (Grania), Cattamanchi, A. (Adithya), Cazabon, D. (Danielle), Crudu, V. (Valeriu), Daftary, A. (Amrita), Dewan, P. (Puneet), Doepel, L.K. (Laurie K), Eisinger, R.W. (Robert W), Fan, V. (Victoria), Fewer, S. (Sara), Furin, J. (Jennifer), Goldhaber-Fiebert, J.D. (Jeremy D), Gomez, G.B. (Gabriela B), Graham, S.M. (Stephen M), Gupta, D. (Devesh), Kamene, M. (Maureen), Khaparde, S. (Sunil), Mailu, E.W. (Eunice W), Masini, E.O. (Enos O), McHugh, L. (Lorrie), Mitchell, E.M.H. (Ellen), Moon, S. (Suerie), Osberg, M. (Michael), Pande, T. (Tripti), Prince, L. (Lea), Rade, K. (Kirankumar), Rao, R. (Raghuram), Remme, M. (Michelle), Seddon, J.A. (James A), Selwyn, C. (Casey), Shete, P. (Priya), Sachdeva, K.S. (Kuldeep S), Stallworthy, G. (Guy), Vesga, J.F. (Juan F), Vilc, V. (Valentina), and Goosby, E.P. (Eric P) more...
- Abstract
___Key messages___ The Commission recommends five priority investments to achieve a tuberculosis-free world within a generation. These investments are designed to fulfil the mandate of the UN High Level Meeting on tuberculosis. In addition, they answer t more...
- Published
- 2019
- Full Text
- View/download PDF
5. Building a tuberculosis-free world: The Lancet Commission on tuberculosis
- Author
-
Reid, MJA, Arinaminpathy, N, Bloom, A, Bloom, BR, Boehm, C, Chaisson, R, Chin, DP, Churchyard, G, Cox, H, Ditiu, L, Dybul, M, Farrar, J, Fauci, AS, Fekodu, E, Fujiwara, PI, Hallett, TB, Hanson, CL, Harrington, M, Herbert, N, Hopewell, PC, Ikeda, C, Jamison, DT, Khan, AJ, Koek, I, Krishnan, N, Motsoaledi, A, Pai, M, Raviglione, MC, Sharman, A, Small, PM, Swaminathan, S, Temesgen, Z, Vassall, A, Venkatesan, N, van Weezenbeek, K, Yamey, G, Agins, BD, Arexandru, S, Andrews, JR, Beyeler, N, Bivol, S, Brigden, G, Cattamanchi, A, Cazabon, D, Crudu, V, Daftary, A, Dewan, P, Doepel, LK, Eisinger, RW, Fan, V, Fewer, S, Furin, J, Goldhaber-Fiebert, JD, Gomez, GB, Graham, SM, Gupta, D, Kamene, M, Khaparde, S, Mailu, EW, Masini, EO, McHugh, L, Mitchell, E, Moon, S, Osberg, M, Pande, T, Prince, L, Rade, K, Rao, R, Remme, M, Seddon, JA, Selwyn, C, Shete, P, Sachdeva, KS, Stallworthy, G, Vesga, JF, Vilc, V, Goosby, EP, Reid, MJA, Arinaminpathy, N, Bloom, A, Bloom, BR, Boehm, C, Chaisson, R, Chin, DP, Churchyard, G, Cox, H, Ditiu, L, Dybul, M, Farrar, J, Fauci, AS, Fekodu, E, Fujiwara, PI, Hallett, TB, Hanson, CL, Harrington, M, Herbert, N, Hopewell, PC, Ikeda, C, Jamison, DT, Khan, AJ, Koek, I, Krishnan, N, Motsoaledi, A, Pai, M, Raviglione, MC, Sharman, A, Small, PM, Swaminathan, S, Temesgen, Z, Vassall, A, Venkatesan, N, van Weezenbeek, K, Yamey, G, Agins, BD, Arexandru, S, Andrews, JR, Beyeler, N, Bivol, S, Brigden, G, Cattamanchi, A, Cazabon, D, Crudu, V, Daftary, A, Dewan, P, Doepel, LK, Eisinger, RW, Fan, V, Fewer, S, Furin, J, Goldhaber-Fiebert, JD, Gomez, GB, Graham, SM, Gupta, D, Kamene, M, Khaparde, S, Mailu, EW, Masini, EO, McHugh, L, Mitchell, E, Moon, S, Osberg, M, Pande, T, Prince, L, Rade, K, Rao, R, Remme, M, Seddon, JA, Selwyn, C, Shete, P, Sachdeva, KS, Stallworthy, G, Vesga, JF, Vilc, V, and Goosby, EP more...
- Published
- 2019
6. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study
- Author
-
Benoît Bernar, Astrid Rojahn, Laura Jones, Elisabeth Schölvinck, Robin Kobbe, Laura Lancella, Delane Shingadia, Fiona Shackley, Lynne McFetridge, Conor Doherty, Cornelius Rau, Nicolaus Schwerk, Oksana Kozdoba, Koen Vanden Driessche, Arnaud G L'Huillier, Jasmin Pfefferle, Srini Bandi, R Song, Andreia Ribeiro, Ivan Solovic, Jonathan P. Glenthoej, Ulrich Heininger, Susana Melendo, Tine Boiy, Uros Krivec, An Bael, Luca Pierantoni, Edda Haberlandt, Miguel Lanaspa, Noémie Wagner, Andrea Lo Vecchio, Francesc Ripoll, Lise Heilmann Jensen, Piero Valentini, Anita Niederer, Roland Berger, Nicole Ritz, Aida M. Gutiérrez-Sánchez, Christelle Christiaens, Franziska Zucol, Katy Fidler, Jolanta Bernatoniene, Anna Starshinova, Volker Strenger, Claus Klingenberg, Ilona Lind, Clare S. Murray, Angela Zacharasiewicz, Ivan Pavic, Amanda Williams, Christina Thir, Vera Chechenyeva, Karsten Kötz, Stephanie Thee, Laura Buchtala, Danilo Buonsenso, Patrick Gavin, Rimvydas Ivaškevicius, Sara Debulpaep, Francesca Ippolita Calò Carducci, Marine Creuven, Beatriz Soto, Srđan Roglić, Lola Falcón, Yvonne Beuvink, Petra Zimmermann, Petra Schelstraete, Lynne Speirs, Daniela S. Kohlfürst, Antoni Noguera-Julian, Mihhail Tistsenko, Steven B. Welch, Hanna Schmid, Anastasios Smyrnaios, Laura Minguell, Andrew Riordan, Michael Buettcher, Angelika Berger, Isabel Carvalho, Daan Van Brusselen, Inga Ivaškeviciene, Matilde Bustillo, Valentina Vilc, Folke Brinkmann, Nina Krajcar, Olaf Neth, Alicia Demirjian, Matthias Bogyi, Ulle Uustalu, Maria Tsolia, Borja Ibanez, Elisabeth Whittaker, Ariane Biebl, Irini Eleftheriou, Burkhard Simma, Petra Prunk, Borbàla Zsigmond, Veronika Osterman, Zoe Oliver, Antoni Soriano-Arandes, Ulrikka Nygaard, Marcello Lanari, Marc Tebruegge, Olga Bilogortseva, Michael Barker, Svetlana Velizarova, Florian Götzinger, Natalia Gabrovska, Begoña Santiago-García, Benhur Şirvan Çetin, Paddy McMaster, Anna Zschocke, Frances Child, Nick Makwana, Mar Santos, Group, ptbnet COVID-19 Study, Gotzinger F., Santiago-Garcia B., Noguera-Julian A., Lanaspa M., Lancella L., Calo Carducci F.I., Gabrovska N., Velizarova S., Prunk P., Osterman V., Krivec U., Lo Vecchio A., Shingadia D., Soriano-Arandes A., Melendo S., Lanari M., Pierantoni L., Wagner N., L'Huillier A.G., Heininger U., Ritz N., Bandi S., Krajcar N., Roglic S., Santos M., Christiaens C., Creuven M., Buonsenso D., Welch S.B., Bogyi M., Brinkmann F., Tebruegge M., Pfefferle J., Zacharasiewicz A., Berger A., Berger R., Strenger V., Kohlfurst D.S., Zschocke A., Bernar B., Simma B., Haberlandt E., Thir C., Biebl A., Vanden Driessche K., Boiy T., Van Brusselen D., Bael A., Debulpaep S., Schelstraete P., Pavic I., Nygaard U., Glenthoej J.P., Heilmann Jensen L., Lind I., Tistsenko M., Uustalu U., Buchtala L., Thee S., Kobbe R., Rau C., Schwerk N., Barker M., Tsolia M., Eleftheriou I., Gavin P., Kozdoba O., Zsigmond B., Valentini P., Ivaskeviciene I., Ivaskevicius R., Vilc V., Scholvinck E., Rojahn A., Smyrnaios A., Klingenberg C., Carvalho I., Ribeiro A., Starshinova A., Solovic I., Falcon L., Neth O., Minguell L., Bustillo M., Gutierrez-Sanchez A.M., Guarch Ibanez B., Ripoll F., Soto B., Kotz K., Zimmermann P., Schmid H., Zucol F., Niederer A., Buettcher M., Cetin B.S., Bilogortseva O., Chechenyeva V., Demirjian A., Shackley F., McFetridge L., Speirs L., Doherty C., Jones L., McMaster P., Murray C., Child F., Beuvink Y., Makwana N., Whittaker E., Williams A., Fidler K., Bernatoniene J., Song R., Oliver Z., Riordan A., Gotzinger, F., Santiago-Garcia, B., Noguera-Julian, A., Lanaspa, M., Lancella, L., Calo Carducci, F. I., Gabrovska, N., Velizarova, S., Prunk, P., Osterman, V., Krivec, U., Lo Vecchio, A., Shingadia, D., Soriano-Arandes, A., Melendo, S., Lanari, M., Pierantoni, L., Wagner, N., L'Huillier, A. G., Heininger, U., Ritz, N., Bandi, S., Krajcar, N., Roglic, S., Santos, M., Christiaens, C., Creuven, M., Buonsenso, D., Welch, S. B., Bogyi, M., Brinkmann, F., Tebruegge, M., Pfefferle, J., Zacharasiewicz, A., Berger, A., Berger, R., Strenger, V., Kohlfurst, D. S., Zschocke, A., Bernar, B., Simma, B., Haberlandt, E., Thir, C., Biebl, A., Vanden Driessche, K., Boiy, T., Van Brusselen, D., Bael, A., Debulpaep, S., Schelstraete, P., Pavic, I., Nygaard, U., Glenthoej, J. P., Heilmann Jensen, L., Lind, I., Tistsenko, M., Uustalu, U., Buchtala, L., Thee, S., Kobbe, R., Rau, C., Schwerk, N., Barker, M., Tsolia, M., Eleftheriou, I., Gavin, P., Kozdoba, O., Zsigmond, B., Valentini, P., Ivaskeviciene, I., Ivaskevicius, R., Vilc, V., Scholvinck, E., Rojahn, A., Smyrnaios, A., Klingenberg, C., Carvalho, I., Ribeiro, A., Starshinova, A., Solovic, I., Falcon, L., Neth, O., Minguell, L., Bustillo, M., Gutierrez-Sanchez, A. M., Guarch Ibanez, B., Ripoll, F., Soto, B., Kotz, K., Zimmermann, P., Schmid, H., Zucol, F., Niederer, A., Buettcher, M., Cetin, B. S., Bilogortseva, O., Chechenyeva, V., Demirjian, A., Shackley, F., Mcfetridge, L., Speirs, L., Doherty, C., Jones, L., Mcmaster, P., Murray, C., Child, F., Beuvink, Y., Makwana, N., Whittaker, E., Williams, A., Fidler, K., Bernatoniene, J., Song, R., Oliver, Z., and Riordan, A. more...
- Subjects
Male ,Delivery of Health Care / organization & administration ,medicine.medical_treatment ,Coronavirus Infections / therapy ,Coronavirus Infections / epidemiology ,law.invention ,Patient Admission ,0302 clinical medicine ,law ,Risk Factors ,COVID-19 ,children ,Europe ,Developmental and Educational Psychology ,030212 general & internal medicine ,Child ,ddc:618 ,Intensive care unit ,Coronavirus ,SARS-CoV-2 ,child ,treatment ,intensive care ,Intensive Care Units ,N/A ,Child, Preschool ,Female ,Europe / epidemiology ,Coronavirus Infections ,Human ,Cohort study ,medicine.medical_specialty ,Pneumonia, Viral / epidemiology ,Intensive Care Unit ,Pneumonia, Viral ,Patient Admission / trends ,Intensive Care Units / organization & administration ,Article ,Follow-Up Studie ,03 medical and health sciences ,Betacoronavirus ,030225 pediatrics ,Internal medicine ,Lower respiratory tract infection ,medicine ,Extracorporeal membrane oxygenation ,Humans ,Pediatrics, Perinatology, and Child Health ,Pandemics ,Pneumonia, Viral / therapy ,Mechanical ventilation ,Betacoronaviru ,Coronavirus Infection ,business.industry ,Risk Factor ,Infant, Newborn ,Infant ,Odds ratio ,medicine.disease ,ptbnet COVID-19 Study Group ,Clinical research ,El Niño ,Pediatrics, Perinatology and Child Health ,business ,Delivery of Health Care ,Follow-Up Studies - Abstract
Background To date, few data on paediatric COVID-19 have been published, and most reports originate from China. This study aimed to capture key data on children and adolescents with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection across Europe to inform physicians and health-care service planning during the ongoing pandemic. Methods This multicentre cohort study involved 82 participating health-care institutions across 25 European countries, using a well established research network—the Paediatric Tuberculosis Network European Trials Group (ptbnet)—that mainly comprises paediatric infectious diseases specialists and paediatric pulmonologists. We included all individuals aged 18 years or younger with confirmed SARS-CoV-2 infection, detected at any anatomical site by RT-PCR, between April 1 and April 24, 2020, during the initial peak of the European COVID-19 pandemic. We explored factors associated with need for intensive care unit (ICU) admission and initiation of drug treatment for COVID-19 using univariable analysis, and applied multivariable logistic regression with backwards stepwise analysis to further explore those factors significantly associated with ICU admission. Findings 582 individuals with PCR-confirmed SARS-CoV-2 infection were included, with a median age of 5·0 years (IQR 0·5–12·0) and a sex ratio of 1·15 males per female. 145 (25%) had pre-existing medical conditions. 363 (62%) individuals were admitted to hospital. 48 (8%) individuals required ICU admission, 25 (4%) mechanical ventilation (median duration 7 days, IQR 2–11, range 1–34), 19 (3%) inotropic support, and one ( Interpretation COVID-19 is generally a mild disease in children, including infants. However, a small proportion develop severe disease requiring ICU admission and prolonged ventilation, although fatal outcome is overall rare. The data also reflect the current uncertainties regarding specific treatment options, highlighting that additional data on antiviral and immunomodulatory drugs are urgently needed. Funding ptbnet is supported by Deutsche Gesellschaft für Internationale Zusammenarbeit. more...
- Published
- 2020
7. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
- Author
-
Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, and Yedilbayev A more...
- Subjects
- Humans, Prospective Studies, Male, Female, Adult, Child, Adolescent, Child, Preschool, Middle Aged, Young Adult, Infant, Administration, Oral, Treatment Outcome, Drug Therapy, Combination, Aged, Tuberculosis, Pulmonary drug therapy, Infant, Newborn, Europe, Cohort Studies, Antitubercular Agents therapeutic use, Antitubercular Agents adverse effects, Antitubercular Agents administration & dosage, Rifampin therapeutic use, Rifampin adverse effects, Rifampin administration & dosage, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
Background: In 2020, WHO guidelines prioritised the use of a standard fully oral short treatment regimen (STR) consisting of bedaquiline, levofloxacin or moxifloxacin, ethionamide, ethambutol, high-dose isoniazid, pyrazinamide, and clofazimine for the management of rifampicin-resistant tuberculosis. A high prevalence of resistance to constituent drugs precluded its widespread use by countries in the WHO European region. We evaluated three 9-month fully oral modified STRs (mSTRs) in which ethionamide, ethambutol, isoniazid, and pyrazinamide were replaced by linezolid, cycloserine, or delamanid (or a combination)., Methods: This multicountry, prospective, single-arm, cohort study examined the effectiveness and safety of mSTRs for fluoroquinolone-susceptible, rifampicin-resistant pulmonary tuberculosis in 13 countries in the WHO European region during 2020-23. We enrolled adults and children of all ages with bacteriologically confirmed rifampicin-resistant, fluoroquinolone-susceptible pulmonary tuberculosis, and children (aged 0-18 years) with clinically diagnosed disease and a confirmed contact with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis. Participants aged 6 years or older received one of two regimens: bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine; or bedaquiline, linezolid, levofloxacin, clofazimine, and delamanid. Children younger than 6 years received delamanid, linezolid, levofloxacin, and clofazimine. Participants were followed up for 12 months after successful treatment completion to detect recurrence and death. The primary outcome was the cumulative probability of not having an unsuccessful study outcome (defined as treatment failure, on-treatment loss to follow-up, death, or recurrence) before 22 months of study follow-up. The primary safety outcome was the incidence of each adverse event of interest (peripheral neuropathy, optic neuritis, myelosuppression, hepatitis, prolonged QT interval, hypokalaemia, and acute kidney injury) of grade 3 or higher severity during the treatment course., Findings: Between Aug 28, 2020 and May 26, 2021, 7272 patients were screened and 2636 were included in the treatment cohort. 1966 (74·6%) were male, 670 (25·4%) were female, and median age was 43 years (IQR 33-53). Treatment success was recorded for 2181 (82·7%) participants. The cumulative probability of not having an unsuccessful study outcome 22 months after treatment initiation was 79% (95% CI 78-81). Increasing age (adjusted hazard ratio 2·61 [95% CI 1·70-4·04] for people aged >64 years vs 35-44 years), HIV-positive status (1·53 [1·16-2·01]), presence of bilateral cavities (1·68 [1·29-2·19]), smoking history (1·34 [1·05-1·71]), baseline anaemia (1·46 [1·15-1·86]), unemployment (1·37 [1·04-1·80]), elevated baseline liver enzymes (1·40 [1·13-1·73]), and excessive alcohol use (1·47 [1·14-1·89]) were positively associated with unsuccessful study outcomes. In the safety cohort of 2813 participants who received at least one dose, 301 adverse events of interest were recorded in 252 (9·0%) participants with the most frequent being myelosuppression (139 [4·9%] participants, 157 [52·2%] events)., Interpretation: The high treatment success and good safety results indicate considerable potential for the use of mSTRs in programmatic conditions, especially for individuals not eligible for the current WHO-recommended 6-month regimen and in settings with a need for alternative options., Funding: The Global Fund to Fight AIDS, Tuberculosis and Malaria; United States Agency for International Development; Government of Germany; and WHO., Translation: For the Russian translation of the abstract see Supplementary Materials section., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2024 World Health Organization. Published by Elsevier Ltd. All rights reserved. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.) more...
- Published
- 2024
- Full Text
- View/download PDF
8. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
- Author
-
Rosu L, Madan JJ, Tomeny EM, Muniyandi M, Nidoi J, Girma M, Vilc V, Bindroo P, Dhandhukiya R, Bayissa AK, Meressa D, Narendran G, Solanki R, Bhatnagar AK, Tudor E, Kirenga B, Meredith SK, Nunn AJ, Bronson G, Rusen ID, Squire SB, and Worrall E more...
- Subjects
- Humans, Cost-Benefit Analysis, Rifampin therapeutic use, Quality of Life, Antitubercular Agents therapeutic use, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
Background: The STREAM stage 2 trial assessed two bedaquiline-containing regimens for rifampicin-resistant tuberculosis: a 9-month all-oral regimen and a 6-month regimen containing an injectable drug for the first 2 months. We did a within-trial economic evaluation of these regimens., Methods: STREAM stage 2 was an international, phase 3, non-inferiority randomised trial in which participants with rifampicin-resistant tuberculosis were randomly assigned (1:2:2:2) to the 2011 WHO regimen (terminated early), a 9-month injectable-containing regimen (control regimen), a 9-month all-oral regimen with bedaquiline (oral regimen), or a 6-month regimen with bedaquiline and an injectable for the first 2 months (6-month regimen). We prospectively collected direct and indirect costs and health-related quality of life data from trial participants until week 76 of follow-up. Cost-effectiveness of the oral and 6-month regimens versus control was estimated in four countries (oral regimen) and two countries (6-month regimen), using health-related quality of life for cost-utility analysis and trial efficacy for cost-effectiveness analysis. This trial is registered with ISRCTN, ISRCTN18148631., Findings: 300 participants were included in the economic analyses (Ethiopia, 61; India, 142; Moldova, 51; Uganda, 46). In the cost-utility analysis, the oral regimen was not cost-effective in Ethiopia, India, Moldova, and Uganda from either a provider or societal perspective. In Moldova, the oral regimen was dominant from a societal perspective. In the cost-effectiveness analysis, the oral regimen was likely to be cost-effective from a provider perspective at willingness-to-pay thresholds per additional favourable outcome of more than US$4500 in Ethiopia, $1900 in India, $3950 in Moldova, and $7900 in Uganda, and from a societal perspective at thresholds of more than $15 900 in Ethiopia, $3150 in India, and $4350 in Uganda, while in Moldova the oral regimen was dominant. In Ethiopia and India, the 6-month regimen would cost tuberculosis programmes and participants less than the control regimen and was highly likely to be cost-effective in both cost-utility analysis and cost-effectiveness analysis. Reducing the bedaquiline price from $1·81 to $1·00 per tablet made the oral regimen cost-effective in the provider-perspective cost-utility analysis in India and Moldova and dominate over the control regimen in the provider-perspective cost-effectiveness analysis in India., Interpretation: At current costs, the oral bedaquiline-containing regimen for rifampicin-resistant tuberculosis is unlikely to be cost-effective in many low-income and middle-income countries. The 6-month regimen represents a cost-effective alternative if injectable use for 2 months is acceptable., Funding: USAID and Janssen Research & Development., Competing Interests: Declaration of interests LR reports consulting fees from GSK (paid to institution) and support for attending trial-related meetings from Janssen Research & Development and the US Agency for International Development (USAID; paid to institution). JJM reports support for attending meetings or travel from the Liverpool School of Tropical Medicine. EMT reports consulting fees from GSK (paid to institution) and support for attending meetings from USAID (paid to institution). MM, PB, RD, GN, AKBh, BK, SKM, AJN, GB, IDR, and EW report support for attending trial-related meetings from Janssen Research & Development and USAID (paid to institution). ET reports support for attending meetings from USAID (paid to institution). SBS reports a research grant on tuberculosis research (paid to institution) from the UK Foreign & Commonwealth Development Office, support for attending trial-related meetings from Janssen Research & Development and USAID (paid to institution), and is co-chair of the Scientific Working Group on Implementation Research for the Tropical Disease Research Foundation (unpaid). All other authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.) more...
- Published
- 2023
- Full Text
- View/download PDF
9. What is behind programmatic treatment outcome definitions for tuberculosis?
- Author
-
Avaliani Z, Gozalov O, Kuchukhidze G, Skrahina A, Soltan V, van den Boom M, Vasilyeva I, Vilc V, and Yedilbayev A
- Subjects
- Antitubercular Agents therapeutic use, Humans, Treatment Outcome, Tuberculosis diagnosis, Tuberculosis drug therapy, Tuberculosis epidemiology, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
Competing Interests: Conflict of interest: Z. Avaliani has nothing to disclose. Conflict of interest: O. Gozalov has nothing to disclose. Conflict of interest: G. Kuchukhidze has nothing to disclose. Conflict of interest: A. Skrahina has nothing to disclose. Conflict of interest: V. Soltan has nothing to disclose. Conflict of interest: M. van den Boom has nothing to disclose. Conflict of interest: I. Vasilyeva has nothing to disclose. Conflict of interest: V. Vilc has nothing to disclose. Conflict of interest: A. Yedilbayev has nothing to disclose. more...
- Published
- 2020
- Full Text
- View/download PDF
10. Assessing tuberculosis control priorities in high-burden settings: a modelling approach.
- Author
-
Vesga JF, Hallett TB, Reid MJA, Sachdeva KS, Rao R, Khaparde S, Dave P, Rade K, Kamene M, Omesa E, Masini E, Omale N, Onyango E, Owiti P, Karanja M, Kiplimo R, Alexandru S, Vilc V, Crudu V, Bivol S, Celan C, and Arinaminpathy N more...
- Subjects
- Bayes Theorem, Cost of Illness, Humans, India epidemiology, Kenya epidemiology, Models, Statistical, Moldova epidemiology, Population Surveillance, Prevalence, Tuberculosis, Pulmonary epidemiology, Tuberculosis, Pulmonary mortality, Health Priorities, Tuberculosis, Pulmonary prevention & control
- Abstract
Background: In the context of WHO's End TB strategy, there is a need to focus future control efforts on those interventions and innovations that would be most effective in accelerating declines in tuberculosis burden. Using a modelling approach to link the tuberculosis care cascade to transmission, we aimed to identify which improvements in the cascade would yield the greatest effect on incidence and mortality., Methods: We engaged with national tuberculosis programmes in three country settings (India, Kenya, and Moldova) as illustrative examples of settings with a large private sector (India), a high HIV burden (Kenya), and a high burden of multidrug resistance (Moldova). We collated WHO country burden estimates, routine surveillance data, and tuberculosis prevalence surveys from 2011 (for India) and 2016 (for Kenya). Linking the tuberculosis care cascade to tuberculosis transmission using a mathematical model with Bayesian melding in each setting, we examined which cascade shortfalls would have the greatest effect on incidence and mortality, and how the cascade could be used to monitor future control efforts., Findings: Modelling suggests that combined measures to strengthen the care cascade could reduce cumulative tuberculosis incidence by 38% (95% Bayesian credible intervals 27-43) in India, 31% (25-41) in Kenya, and 27% (17-41) in Moldova between 2018 and 2035. For both incidence and mortality, modelling suggests that the most important cascade losses are the proportion of patients visiting the private health-care sector in India, missed diagnosis in health-care settings in Kenya, and drug sensitivity testing in Moldova. In all settings, the most influential delay is the interval before a patient's first presentation for care. In future interventions, the proportion of individuals with tuberculosis who are on high-quality treatment could offer a more robust monitoring tool than routine notifications of tuberculosis., Interpretation: Linked to transmission, the care cascade can be valuable, not only for improving patient outcomes but also in identifying and monitoring programmatic priorities to reduce tuberculosis incidence and mortality., Funding: US Agency for International Development, Stop TB Partnership, UK Medical Research Council, and Department for International Development., (Copyright © 2019 The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.) more...
- Published
- 2019
- Full Text
- View/download PDF
11. Building a tuberculosis-free world: The Lancet Commission on tuberculosis.
- Author
-
Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione MC, Sharman A, Small PM, Swaminathan S, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Agins BD, Alexandru S, Andrews JR, Beyeler N, Bivol S, Brigden G, Cattamanchi A, Cazabon D, Crudu V, Daftary A, Dewan P, Doepel LK, Eisinger RW, Fan V, Fewer S, Furin J, Goldhaber-Fiebert JD, Gomez GB, Graham SM, Gupta D, Kamene M, Khaparde S, Mailu EW, Masini EO, McHugh L, Mitchell E, Moon S, Osberg M, Pande T, Prince L, Rade K, Rao R, Remme M, Seddon JA, Selwyn C, Shete P, Sachdeva KS, Stallworthy G, Vesga JF, Vilc V, and Goosby EP more...
- Subjects
- Cost of Illness, Disease Eradication, Global Health statistics & numerical data, Goals, Health Policy, Health Priorities, Humans, Incidence, Leadership, Mortality, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis pathogenicity, Political Systems, Quality of Health Care standards, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary epidemiology, World Health Organization economics, Global Health legislation & jurisprudence, Quality of Health Care trends, Research economics, Tuberculosis, Pulmonary economics, Tuberculosis, Pulmonary prevention & control
- Published
- 2019
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.